Wells Fargo & Company MN raised its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 202.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 130,374 shares of the biotechnology company’s stock after acquiring an additional 87,212 shares during the quarter. Wells Fargo & Company MN owned approximately 0.24% of Heron Therapeutics worth $2,106,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the business. Trexquant Investment LP purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $206,000. Chartwell Investment Partners LLC purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $2,340,000. C WorldWide Group Holding A S purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $1,615,000. Asymmetry Capital Management L.P. purchased a new position in shares of Heron Therapeutics in the third quarter valued at about $1,017,000. Finally, Fisher Asset Management LLC purchased a new position in shares of Heron Therapeutics during the third quarter valued at about $1,621,000. Hedge funds and other institutional investors own 98.21% of the company’s stock.
In related news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 19.93% of the company’s stock.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. analysts expect that Heron Therapeutics Inc will post -3.38 EPS for the current fiscal year.
HRTX has been the topic of several research analyst reports. Mizuho reiterated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research report on Friday, December 8th. Oppenheimer initiated coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They set a “buy” rating and a $27.00 price target on the stock. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Friday, October 20th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $28.82.
ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Has $2.11 Million Holdings in Heron Therapeutics Inc (HRTX)” was first reported by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://weekherald.com/2018/01/17/wells-fargo-company-mn-has-2-11-million-holdings-in-heron-therapeutics-inc-hrtx.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.